Frequently Asked Questions About Cardiac NAM Platforms

---

A cardiac NAM (New Approach Methodology) platform is a human-relevant, non-animal testing system used to evaluate cardiac safety, disease mechanisms, or drug efficacy in vitro. These platforms may include engineered heart tissues, microphysiological systems, or multicellular cardiac organoids. Cardiac NAM platforms aim to provide mechanistically informative data while reducing reliance on animal models in drug development.

Traditional cardiac safety assessment often relies on 2D cardiomyocyte assays and animal models. Cardiac NAM platforms expand upon these approaches by incorporating advanced architectures such as structured tissues, microfluidic systems, or multicellular 3D models. These systems can provide broader tissue-level insight, mechanistic information, and improved human relevance.

Yes. Multicellular human cardiac organoids are considered a class of cardiac NAM technologies. By integrating multiple cardiac cell types within a three-dimensional microenvironment, cardiac organoids enable evaluation of coordinated tissue-level responses in vitro. Their human origin and mechanistic readouts align with NAM principles.

Depending on architecture, cardiac NAM platforms may measure:

• Contractility and force generation
• Electrophysiological stability
• Calcium handling
• Metabolic activity
• Biomarker release
• Transcriptomic and molecular pathway activation

Advanced systems may integrate functional and molecular endpoints to support translational interpretation.

Regulatory authorities such as the U.S. FDA and European agencies increasingly encourage the integration of New Approach Methodologies into nonclinical development programs. While NAM platforms typically complement rather than fully replace traditional methods, they are being incorporated into integrated pharmacology and safety assessment strategies.

Examples of cardiac NAM technologies include:

• Human iPSC-derived cardiomyocyte systems
• Engineered heart tissue platforms
• Cardiac microphysiological systems (organ-on-chip)
• Multicellular human cardiac organoids

Each approach provides distinct advantages depending on study objectives and required endpoints.

Cardiac responses to drugs often involve coordinated interactions between cardiomyocytes, endothelial cells, stromal elements, and immune components. Multicellular cardiac NAM systems aim to reflect aspects of this complexity, enabling evaluation of intercellular signaling and integrated tissue-level responses.

Cardiac NAM systems are powerful — but not universally appropriate.

They may be less suitable when:

The primary question is systemic, not cardiac

If safety concerns involve complex whole-organism pharmacokinetics, immune-mediated multi-organ effects, or off-target systemic interactions beyond cardiac tissue, isolated cardiac NAM systems may provide incomplete context.

The mechanism is well-characterized and low-risk

For compounds with well-understood cardiac pharmacology and extensive historical data, incremental NAM data may not materially change decision-making.

Ultra-high throughput screening is the sole priority

Certain early-stage programs require extremely high-throughput, low-cost triage platforms where simpler 2D assays may be more operationally efficient.

The platform lacks defined context-of-use

NAM deployment without a clearly articulated decision framework can generate data without actionable impact. Platforms should be selected based on specific development questions.

Regulatory strategy does not incorporate NAM evidence

If a development plan does not integrate NAM data into regulatory discussions or decision documents, the strategic value may be limited.